Improving Lives Through Nuclear Medicine™

Medical and R&D


Targeted Radiotherapy in

Jubilant Radiopharma is proud to be a leader in the development of therapeutics intended to treat rare and serious conditions. These efforts are aligned with the Value that Nuclear Medicine can bring to improve precise, patient focused treatment.

Neuroblastoma is a difficult to treat childhood cancer and those children with resistant or relapsed disease, after current treatment options are exhausted, have very poor survival.

Our investigational agent is currently being studied under clinical research protocols. Please consult those organizations at:

NANT (New Approaches to Neuroblastoma Therapy)

COG (Children’s Oncology Group)

For additional information please consult:

NOTE: MIBG labeled with I-131 is currently not approved by the USFDA or Health Canada


We use cookies to recognize your repeat visits and preferences, as well as to measure the effectiveness
of campaigns and analyze traffic. If you continue to use this site we will assume your acceptance.